Resonance Health Akcie

Resonance Health Dluh/EBITDA

Poměr Celkového Dluhu k EBITDA společnosti Resonance Health (RHT.AX) k datu 14. 8. 2026 je -4,34. V předchozím roce byl Poměr Celkového Dluhu k EBITDA -22,09 — změna o -80,34 % (vyšší).

Dluh/EBITDA

-4,34

YoY

-80,34%

Poslední aktualizace:

Poměr Celkového Dluhu k EBITDA společnosti Resonance Health je 2026 -4,34 . Poměr Celkového Dluhu k EBITDA společnosti Resonance Health byl 2025 -22,09 . Klesá tak o -80,34% vyšší než v předchozím roce.
Access this data via the Eulerpool API

Resonance Health Analýza akcií

Co dělá Resonance Health? Resonance Health Ltd is an Australian company that operates in the medical technology industry. The company's business model is to offer groundbreaking solutions for the diagnosis and treatment of liver and iron diseases. As a pioneering company in the development of methods and technologies for quantifying liver and iron concentrations, Resonance Health continually sets new standards in the industry. The company was founded in 2000 by a team of biomedicine professionals from the University of Western Australia. Over the years, the company has gained a lot of experience and constantly evolved to keep up with the progress of medical technology. The goal is to provide patients with better treatment and improved quality of life. One division of the company is the development and manufacturing of diagnostic tools for quantifying liver and iron diseases such as hepatitis, fatty liver, or hemochromatosis. The quantification method used by Resonance Health is called FerriScan. This method is non-invasive and painless, using magnetic resonance imaging (MRI) to measure the concentration of iron in the tissue. This is particularly important as a change in iron content can indicate a progressing liver disease. In addition to the FerriScan diagnostic tool, Resonance Health also offers a software package for analyzing FerriScan results, which is used by physicians and clinicians to assess disease progression. Furthermore, the company also develops solutions in the field of hemochromatosis, a genetic disorder that can lead to increased iron levels in the body. Another division of Resonance Health is the provision of research and development services to further develop and improve FerriScan and other technologies. The company collaborates with other companies, scientific institutions, and universities to advance the current developments in liver and iron diagnostics. Resonance Health has a range of products that contribute to better diagnosis and treatment of liver and iron diseases. These include FerriScan, the FerriSmart software package for precise monitoring of iron and liver health, and Hepatica, a software supporting hospitals and clinics in the diagnosis of liver diseases. The company is an innovative leader in the industry, contributing to improving the quality of life for patients. The products and services of Resonance Health have helped doctors and clinicians to effectively treat and diagnose liver and iron diseases. Additionally, the company has established a strong scientific foundation and works closely with leading institutions to continuously develop innovative solutions. Resonance Health is a company with a rich history that continues to evolve to meet the demands of the medical technology industry. The company aims to continuously improve the diagnosis and treatment of liver and iron diseases and offer better solutions. Resonance Health je jednou z nejoblíbenějších společností na Eulerpool.com.

Často kladené otázky ohledně akcií Resonance Health

Poměr Celkového Dluhu k EBITDA společnosti Resonance Health činí -4,34 v roce 2026.

Poměr Celkového Dluhu k EBITDA společnosti Resonance Health se změnilo z -22,09 na -4,34, což představuje změnu o -80,34 %. Hodnota je vyšší než v předchozím roce.

Na Eulerpool najdete úplný historický vývoj Poměr Celkového Dluhu k EBITDA Resonance Health od roku 2006 – s ročními hodnotami, grafy a podrobnou analýzou.

Dluh/EBITDA měří celkový dluh v poměru k zisku před úroky, daněmi a odpisy. Ukazuje roky potřebné k splacení veškerého dluhu z EBITDA.

Dobrá hodnota se liší podle odvětví a fáze vývoje společnosti. Na Eulerpool můžete porovnat Resonance Health společnosti Poměr Celkového Dluhu k EBITDA s porovnatelnými společnostmi a průměrem odvětví, abyste určili, zda je atraktivní.

Access this data via the Eulerpool API

Páka — Resonance Health

Všechny klíčové ukazatele — Resonance Health